HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Oncology
Phase III
Real-world study shows lenalidomide-dexamethasone yields 22.9-month PFS in transplant-ineligible myeloma
Real-world study shows lenalidomide treatment outcomes for older multiple myeloma patients
A prospective, non-interventional study of 168 transplant-ineligible NDMM patients in Germany found median PFS of 22.9 months and OS of 58.1…
Real-world data shows lenalidomide plus low-dose dexamethasone keeps older multiple myeloma patients disease-free for nearly two years while…
Apr 3, 2026
Pulmonology & Critical Care
RCT
Antenatal dexamethasone reduces respiratory support need in late preterm infants in Vietnamese RCT
Can a steroid shot before late preterm birth help babies breathe easier?
A randomized controlled trial of 294 pregnant women at risk of late preterm delivery in Vietnam found antenatal dexamethasone reduced infant…
Giving mothers a steroid shot before late preterm birth cut the need for breathing support in babies by nearly 10%, reducing hospital stays …
Apr 2, 2026
Anesthesiology & Pain Medicine
RCT
Perineural dexamethasone extends analgesia duration in upper limb surgery blocks versus bupivacaine alone
Can a common steroid make pain relief from arm surgery last longer?
A double-blinded RCT in 90 ASA I/II patients undergoing upper limb procedures found adding 4 mg perineural dexamethasone to bupivacaine sign…
Adding a tiny amount of common steroid dexamethasone to arm surgery numbing shots nearly doubled pain relief time to over 20 hours with few …
Apr 2, 2026
Hematology
Phase II
Daratumumab + Len/Dex shows ORR in relapsed/refractory multiple myeloma phase 1/2 trial
Can a new drug combination help people with multiple myeloma that has returned after treatment?
This phase 1/2 study evaluated daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed-refracto…
A new three-drug combination of daratumumab, lenalidomide, and dexamasone showed safety and response in people with relapsed multiple myelom…
CT.gov
Mar 30, 2026